Latest Cardiac Biomarkers Companies Update:
Abbott (US) Received FDA approval for its Elevate™ assay, a new generation high-sensitivity troponin test offering improved accuracy for early detection of heart attacks.
Roche (Switzerland) Collaborated with Mayo Clinic to develop a novel blood test based on a combination of cardiac biomarkers and AI algorithms for diagnosing heart failure with improved accuracy.
Siemens Healthineers (Germany) Launched the Atellica® CHD 99 test, a multi-biomarker panel for comprehensive assessment of cardiovascular disease risk, including detection of acute and chronic myocardial injuries.
Quidel Corporation (US) Developed the Sofia® BNP test, a rapid point-of-care test for measuring B-type natriuretic peptide, a key biomarker for heart failure diagnosis and management.
Alnylam Pharmaceuticals (US) Focused on developing RNA interference (RNAi) therapeutics targeting cardiac biomarkers for early intervention and prevention of cardiovascular diseases.
List of Cardiac Biomarkers Key companies in the market
- Novartis AG (Switzerland)
- Quidel Corporation (US)
- ACS Biomarker B.V (Netherlands)
- Randox Laboratories Ltd (UK)
- Trivitron Healthcare (India)
- Hoffman La Roche Ltd (Switzerland)
- Johnson & Johnson Services Inc. (US)
- Abbott Laboratories (US)
- Siemens (Germany)
- Thermo Fisher Scientific Inc (US)